CA3034332A1 - Kinase inhibitor compounds, compositions, and methods of treating cancer - Google Patents

Kinase inhibitor compounds, compositions, and methods of treating cancer Download PDF

Info

Publication number
CA3034332A1
CA3034332A1 CA3034332A CA3034332A CA3034332A1 CA 3034332 A1 CA3034332 A1 CA 3034332A1 CA 3034332 A CA3034332 A CA 3034332A CA 3034332 A CA3034332 A CA 3034332A CA 3034332 A1 CA3034332 A1 CA 3034332A1
Authority
CA
Canada
Prior art keywords
alkyl
mmol
compound
dmso
mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3034332A
Other languages
English (en)
French (fr)
Inventor
Arvin C. Dar
Ross L. Cagan
Alex P. SCOPTON
Masahiro Sonoshita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai filed Critical Icahn School of Medicine at Mount Sinai
Publication of CA3034332A1 publication Critical patent/CA3034332A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3034332A 2016-08-17 2017-08-17 Kinase inhibitor compounds, compositions, and methods of treating cancer Pending CA3034332A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376138P 2016-08-17 2016-08-17
US62/376,138 2016-08-17
PCT/US2017/047383 WO2018035346A1 (en) 2016-08-17 2017-08-17 Kinase inhibitor compounds, compositions, and methods of treating cancer

Publications (1)

Publication Number Publication Date
CA3034332A1 true CA3034332A1 (en) 2018-02-22

Family

ID=61197083

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3034332A Pending CA3034332A1 (en) 2016-08-17 2017-08-17 Kinase inhibitor compounds, compositions, and methods of treating cancer

Country Status (6)

Country Link
US (2) US10519113B2 (enExample)
EP (1) EP3500257B1 (enExample)
JP (1) JP2019528279A (enExample)
CN (1) CN110072526A (enExample)
CA (1) CA3034332A1 (enExample)
WO (1) WO2018035346A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108440404A (zh) * 2018-05-08 2018-08-24 西安凯伦生物科技有限公司 具有多重激酶抑制作用的抗肿瘤药物及其制备方法和应用
CN111362871B (zh) * 2018-12-25 2022-05-17 北京福元医药股份有限公司 取代的吡啶-2-甲酰胺类化合物及其用途
US20220387630A1 (en) 2020-02-27 2022-12-08 National University Corporation Hokkaido University Method for screening anticancer agent and combination drug of kinase inhibitors for treatment of pancreatic cancer
CN113402456B (zh) * 2020-03-16 2023-03-03 深圳大学 一种抗肿瘤药物以及一种化合物或其药学上可接受的盐在抗肿瘤药物中的应用
AU2021268210A1 (en) * 2020-05-08 2022-12-15 Georgiamune, Inc. Akt3 modulators
EP4237093A4 (en) * 2020-11-02 2024-06-12 Icahn School of Medicine at Mount Sinai METHODS OF TREATING TUMORS AND CANCERS WITH DEREGULATED WNT SIGNALING PATHWAYS
KR102710925B1 (ko) * 2021-06-01 2024-09-27 부산대학교 산학협력단 신규 스퀘어아마이드 유도체 및 이의 용도
WO2025083280A1 (en) * 2023-10-19 2025-04-24 Universitat De Barcelona Sorafenib analogs for use in the treatment of cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE300299T1 (de) * 1997-12-22 2005-08-15 Bayer Pharmaceuticals Corp Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen
US7235576B1 (en) * 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
PT1580188E (pt) * 2002-02-11 2012-01-25 Bayer Healthcare Llc Aril-ureias como inibidores de cinases
WO2004014870A1 (en) 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
EP1608639A2 (en) * 2003-02-28 2005-12-28 Bayer Pharmaceuticals Corporation Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
WO2004078746A2 (en) * 2003-02-28 2004-09-16 Bayer Pharmaceuticals Corporation 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatrory disorders
JP4860474B2 (ja) * 2003-05-20 2012-01-25 バイエル、ファーマシューテイカルズ、コーポレイション Ｐｄｇｆｒによって仲介される病気のためのジアリール尿素
EP1641759B1 (en) * 2003-07-07 2014-03-12 Merck Patent GmbH Malonamide derivatives
CL2004001834A1 (es) 2003-07-23 2005-06-03 Bayer Pharmaceuticals Corp Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
ATE395905T1 (de) * 2004-08-27 2008-06-15 Bayer Pharmaceuticals Corp Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs
ES2480440T3 (es) * 2005-12-21 2014-07-28 Bayer Intellectual Property Gmbh Derivados sustituidos de pirimidina útiles en el tratamiento del cáncer y de otros trastornos
WO2008082730A2 (en) * 2006-09-19 2008-07-10 Novartis Ag Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
CN101260106A (zh) * 2007-03-06 2008-09-10 中国药科大学 Raf激酶抑制剂及其制备方法和用途
US20090012091A1 (en) * 2007-07-02 2009-01-08 Kinagen, Inc. Oximide derivatives and their therapeutical application
CN101723890B (zh) * 2008-10-10 2011-11-23 中国科学院成都生物研究所 芳基硫脲及其制备方法和用途
JP2011063516A (ja) * 2009-09-15 2011-03-31 Daiichi Sankyo Co Ltd アミド誘導体
WO2011046991A2 (en) * 2009-10-15 2011-04-21 Gilead Connecticut, Inc. Certain substituted ureas as modulators of kinase activity
EP2675274B1 (en) * 2011-02-14 2017-05-03 The Regents of The University of California SORAFENIB DERIVATIVES AS sEH INHIBITORS
US9090617B1 (en) * 2011-08-03 2015-07-28 National Taiwan University Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same
PL2739139T3 (pl) * 2011-08-03 2020-06-15 National Taiwan University Agoniści białkowej fosfatazy tyrozynowej 1 zawierającej domeny homologii z src 2 i sposoby leczenia z ich zastosowaniem
CN103508961B (zh) * 2012-06-26 2015-07-22 中美冠科生物技术（太仓）有限公司 抗肿瘤药物
US10449182B2 (en) * 2012-07-06 2019-10-22 The Regents Of The University Of California Sorafenib derivatives as p21 inhibitors
WO2015051149A1 (en) * 2013-10-04 2015-04-09 The Trustees Of Columbia University In The City Of New York Sorafenib analogs and uses thereof

Also Published As

Publication number Publication date
JP2019528279A (ja) 2019-10-10
WO2018035346A1 (en) 2018-02-22
EP3500257A1 (en) 2019-06-26
US11066370B2 (en) 2021-07-20
EP3500257A4 (en) 2020-01-22
CN110072526A (zh) 2019-07-30
US20200325103A1 (en) 2020-10-15
US10519113B2 (en) 2019-12-31
EP3500257B1 (en) 2025-07-02
US20190202789A1 (en) 2019-07-04
WO2018035346A8 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
EP3500257B1 (en) Kinase inhibitor compounds, compositions, and methods of treating cancer
CA2969090C (en) Triazolopyrimidine compounds and uses thereof
JP5825535B2 (ja) Ｈｅｃ１活性の調節因子およびそのための方法
CA3203205A1 (en) Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer
CA2868081C (en) Inhibition of mcl-1 and/or bfl-1/a1
JP5885012B2 (ja) Ｋｉｔ阻害剤に対して獲得した抵抗性を有する癌の処置
US8071795B2 (en) HIF inhibitors
CA3189410A1 (en) Kat6 inhibitor methods and combinations for cancer treatment
Aridoss et al. Structure–Activity Relationship (SAR) Study of Ethyl 2-Amino-6-(3, 5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4 H-chromene-3-carboxylate (CXL017) and the Potential of the Lead against Multidrug Resistance in Cancer Treatment
TW202019407A (zh) Bcl-2抑制劑與MDM2抑制劑的組合產品及其在預防及/或治療疾病中的用途
Nandikolla et al. Synthesis, study of antileishmanial and antitrypanosomal activity of imidazo pyridine fused triazole analogues
JP2018508563A (ja) Ｕｓｐ７阻害剤化合物及び使用方法
Reutershan et al. Discovery of MK-4688: an efficient inhibitor of the HDM2–p53 protein–protein interaction
TW201643143A (zh) 抑制氧化壓迫引發的神經細胞死亡之化合物
JP2025511974A (ja) がんの治療のためのラクテート／ＡＴＰ産生阻害剤としてのＮ－（３－（ベンゾ［ｂ］チオフェン－２－カルボキシアミド）－フェニル）－２，３－ジヒドロベンゾ［ｂ］［１，４］ジオキシン－６－カルボキシアミド誘導体及び関連化合物
CA2931804A1 (en) Piperidine and piperazine derivatives and their use in treating viral infections and cancer
Li et al. Imidazo [1, 2-a] pyridine derivatives as novel dual-target inhibitors of ABCB1 and ABCG2 for reversing multidrug resistance
ES2607807T3 (es) Procedimiento para la preparación de los inibidores de las quinasas c-fms
Khetmalis et al. Design, synthesis, and anti-mycobacterial evaluation of 1, 8-naphthyridine-3-carbonitrile analogues
Zhang et al. Design, synthesis, and bioevaluation of novel NLRP3 inhibitor with IBD immunotherapy from the virtual screen
Yuan et al. Pioneering 4, 11-Dioxo-4, 11-dihydro-1 H-anthra [2, 3-d] imidazol-3-ium Compounds as Promising Survivin Inhibitors by Targeting ILF3/NF110 for Cancer Therapy
Shi et al. Discovery of a novel dihydroisoquinolinone derivative as a potent CDK9 inhibitor capable of overcoming L156F mutant for the treatment of hematologic malignancies
CA2951924A1 (en) Heterocyclic compounds and methods of use thereof
Bian et al. Discovery of Orally Efficacious Bridged Piperazines as smTNF Modulators
HK40010493A (en) Kinase inhibitor compounds, compositions, and methods of treating cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220809

EEER Examination request

Effective date: 20220809

EEER Examination request

Effective date: 20220809

EEER Examination request

Effective date: 20220809